tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
XOMA’s Strategic Expansion and Mezagitamab’s Market Potential Drive Buy Rating
PremiumRatingsXOMA’s Strategic Expansion and Mezagitamab’s Market Potential Drive Buy Rating
2M ago
Xoma purchases mezagitamab royalty, milestone rights for up to $30M
Premium
The Fly
Xoma purchases mezagitamab royalty, milestone rights for up to $30M
2M ago
Xoma’s Strong Financial Performance and Promising Pipeline Developments Support Buy Rating
Premium
Ratings
Xoma’s Strong Financial Performance and Promising Pipeline Developments Support Buy Rating
2M ago
Xoma initiated with a Buy at Benchmark
PremiumThe FlyXoma initiated with a Buy at Benchmark
3M ago
Xoma completes sale of Kinnate Pipeline assets for up to $270M
Premium
The Fly
Xoma completes sale of Kinnate Pipeline assets for up to $270M
3M ago
Strategic Growth Potential: Xoma’s Diversified Royalty Portfolio and Promising Phase 3 Asset
Premium
Ratings
Strategic Growth Potential: Xoma’s Diversified Royalty Portfolio and Promising Phase 3 Asset
4M ago
Ligand leads $75M royalty financing in Castle Creek
PremiumThe FlyLigand leads $75M royalty financing in Castle Creek
5M ago
Xoma price target lowered to $104 from $123 at H.C. Wainwright
Premium
The Fly
Xoma price target lowered to $104 from $123 at H.C. Wainwright
6M ago
Xoma price target raised to $123 from $117 at H.C. Wainwright
Premium
The Fly
Xoma price target raised to $123 from $117 at H.C. Wainwright
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100